에 대한 최신 뉴스 Arcellx (NASDAQ:ACLX) 주식

ARCELLX INC

Arcellx

Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.

Gilead Sciences Inc.

Analyst Color

Biotech

Earnings

Large Cap

News

Guidance

Health Care

Analyst Ratings

Movers

Trading Ideas

General

ACLX

GILD

길리어드 사이언스(NASDAQ:GILD)의 주식은 수요일 7% 이상 상승 마감했다. 이는 화요일 회사가 2024년 4분기 조정 EPS가 1.90달러로, 컨센서스 1.70달러를 초과했다고 보고한 이후의 일이다.

길리어드, 2025년 전망 상향 조정 및 HIV 예방을 위한 레나카파비르 출시 목표

Arcellx Inc

Management

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Avadel Pharmaceuticals Appoints Susan Rodriguez As COO

The first contract is for airfield assets and includes the runways, taxiways, aircraft parking areas, and air traffic control towers. The second contract is for landside infrastructure packages including roads, utilities, tunnels, bridges, rail network, and landscaping. As DP, Parsons will provide project management services for all phases of both contracts including early development, design, permits and approvals, procurement, construction, commissioning, handover, and overall coordination.

Contracts

Parsons Awarded Two Delivery Partner Contracts From King Salman International Airport Development Company

CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) reported quarterly earnings of $0.07 per share which met the analyst consensus estimate. This is a 14.75 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $110.90 million which missed the analyst consensus estimate of $111.48 million by 0.52 percent. This is a 4.86 percent increase over sales of $105.76 million the same period last year.

Earnings Misses

CINT

CI&T Q1 Adj. EPS $0.07, Inline, Sales $110.90M Miss $111.48M Estimate

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 48 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $321.00 thousand which beat the analyst consensus estimate of $291.67 thousand by 10.06 percent. This is a 35.28 percent decrease over sales of $496.00 thousand the same period last year.

Earnings Beats

DRRX

Durect Q1 EPS $(0.13) Misses $(0.12) Estimate, Sales $321.00K Beat $291.67K Estimate

Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) affirms FY2025 sales outlook from $285.00 million-$288.00 million to $285.00 million-$288.00 million vs $285.56 million estimate.

SMWB

Similarweb Affirms FY2025 Sales Guidance of $285.00M-$288.00M vs $285.56M Est

Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) sees Q2 sales of $68.000 million-$69.000 million vs $66.29 million analyst estimate.

Similarweb Sees Q2 Sales $68.000M-$69.000M vs $66.29M Est

Global Star Acquisition Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLST#NASDAQ">GLST</a>) ("Global Star"), a special purpose acquisition company and K Enter Holdings Inc. ("K Enter"), a holding company with an internal K drama production team and controlling interest in six diversified entertainment operating companies based in Korea and engaged in the entertainment content and IP creation businesses, today announced the completion of the previously announced business combination that will result in the creation of K Wave Media Ltd. Accordingly, K Wave Media Ltd.'s ordinary shares and warrants are expected to commence trading on The Nasdaq Global Market under the symbols "KWM" and "KWMWW", respectively on May&nbsp;14, 2025.
The business combination was approved at a special meeting of GLST's stockholders on February&nbsp;3, 2025.

GLST

Global Star Acquisition And K Enter Complete Business Combination To Form K Wave Media Ltd. With Shares To Begin Trading On Nasdaq As "KWM"

GEN Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.01) by 500 percent. This is a 154.55 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $57.34 million which missed the analyst consensus estimate of $57.42 million by 0.15 percent. This is a 12.96 percent increase over sales of $50.76 million the same period last year.

GENK

GEN Restaurant Gr Q1 EPS $(0.06) Misses $(0.01) Estimate, Sales $57.34M Miss $57.42M Estimate

Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.50) by 2 percent. This is a 188.24 percent decrease over losses of $(0.17) per share from the same period last year.

GUTS

Fractyl Health Q1 EPS $(0.49) Beats $(0.50) Estimate

Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $2.14 million which missed the analyst consensus estimate of $2.81 million by 24.09 percent. This is a 35.14 percent decrease over sales of $3.29 million the same period last year.

HYPR

Hyperfine Q1 EPS $(0.12), Inline, Sales $2.14M Miss $2.81M Estimate

Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is a 150 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $67.10 million which beat the analyst consensus estimate of $66.29 million by 1.22 percent. This is a 13.76 percent increase over sales of $58.98 million the same period last year.

Similarweb Q1 Adj. EPS $(0.02) Misses $(0.01) Estimate, Sales $67.10M Beat $66.29M Estimate

Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) shares are trading higher by 7.5% to $357.11 since reporting first-quarter results on April 29. The company&#8217;s earnings beat has been a key catalyst for the stock amid strong margin performance.
What To Know: The company <a href="https://www.benzinga.com/news/earnings/25/04/45080514/sherwin-williams-reports-mixed-q1-results-in-choppy-demand-environment">posted</a> first-quarter adjusted earnings per share of $2.25, beating estimates of $2.16, despite a 1.1% year-over-year dip in revenue to $5.31 billion. Sales in the Paint Stores Group grew 1.2%, offsetting softness in the Consumer Brands and Performance Coatings divisions. 
CEO Heidi Petz emphasized cost control and margin expansion as key drivers behind the results and reaffirmed full-year adjusted EPS guidance of $11.65 to $12.05.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/05/45387898/plug-power-stock-is-tumbling-tuesday-whats-going-on">Plug Power Stock Is Tumbling Tuesday: What&#8217;s Going On?</a>
Analysts have responded positively. On April 30, Wells Fargo upgraded Sherwin-Williams from Equal-Weight to Overweight and raised its price target from $350 to $420.
RBC Capital Markets followed on May 1, maintaining an Outperform rating and increasing its price target from $410 to $420. Both analysts see a 17.6% potential upside from current levels.
The company continues to <a href="https://www.benzinga.com/pressreleases/25/04/n45062385/the-sherwin-williams-company-reports-2025-first-quarter-financial-results">return capital aggressively</a>, repurchasing $351.7 million in shares and raising its dividend by 10.5% in the first quarter. Sherwin-Williams projects full-year revenue growth in the low-single-digit range, expecting ongoing demand softness in several markets.
<h1 class="wp-block-heading">How To Buy SHW Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, with Sherwin-Williams, it is in the Materials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SHW has a 52-week high of $400.42 and a 52-week low of $282.09.
Read Also: • <a href="https://www.benzinga.com/news/earnings/25/05/45388163/hertz-global-shares-are-plunging-following-q1-earnings-miss-whats-driving-the-sell-off">Hertz Global Shares Are Plunging Following Q1 Earnings Miss: What&#8217;s Driving The Sell-Off?</a>
Photo: JHVEPhoto/Shutterstock

Sherwin-Williams (SHW) Stock Gains On Recent Q1 Earnings Beat, Dividend Hike

SEER

Seer Affirms FY2025 Sales Guidance of $17.00M-$18.00M vs $17.16M Est

MDAI

Spectral AI Widens FY2025 Sales Guidance from $21.50M to $20.50M-$21.50M vs $21.78M Est

Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.76) by 14.47 percent. This is a 22.62 percent increase over losses of $(0.84) per share from the same period last year. The company reported quarterly sales of $13.19 million which beat the analyst consensus estimate of $6.17 million by 113.92 percent. This is a 44.90 percent increase over sales of $9.10 million the same period last year.

MGNX

Macrogenics Q1 EPS $(0.65) Beats $(0.76) Estimate, Sales $13.19M Beat $6.17M Estimate

Dawson Geophysical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWSN#NASDAQ">DWSN</a>) reported quarterly earnings of $0.03 per share. This is a 84.21 percent decrease over earnings of $0.19 per share from the same period last year. The company reported $16.08 million in sales this quarter. This is a 49.09 percent decrease over sales of $31.58 million the same period last year.

DWSN

Dawson Geophysical Q1 EPS $0.03 Down From $0.19 YoY, Sales $16.08M Down From $31.58M YoY

CarParts.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTS#NASDAQ">PRTS</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.12) by 125 percent. This is a 145.45 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $147.38 million which beat the analyst consensus estimate of $146.14 million by 0.84 percent. This is a 11.37 percent decrease over sales of $166.29 million the same period last year.

PRTS

CarParts.com Q1 EPS $(0.27) Misses $(0.12) Estimate, Sales $147.38M Beat $146.14M Estimate

CAE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAE#NYSE">CAE</a>) reported quarterly earnings of $0.33 per share which missed the analyst consensus estimate of $0.46 by 28.26 percent. This is a 22.22 percent increase over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $888.47 million which missed the analyst consensus estimate of $1.29 billion by 31.27 percent. This is a 6.32 percent increase over sales of $835.64 million the same period last year.

CAE Q4 Adj. EPS $0.33 Misses $0.46 Estimate, Sales $888.47M Miss $1.29B Estimate

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.15) by 20 percent. This is a 5.88 percent decrease over losses of $(0.17) per share from the same period last year.

BEAT

HeartBeam Q1 EPS $(0.18) Misses $(0.15) Estimate

Evolution Petroleum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EPM#AMEX">EPM</a>) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 33.33 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $22.56 million which beat the analyst consensus estimate of $22.37 million by 0.87 percent. This is a 2.02 percent decrease over sales of $23.02 million the same period last year.

Evolution Petroleum Q3 Adj. EPS $0.02, Inline, Sales $22.56M Beat $22.37M Estimate

Press Releases

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

ADMA Biologics

Akero Therapeutics

Alvotech

Apogee Therapeutics

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Immunovant

Krystal Biotech

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Veracyte

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

Scotiabank

HC Wainwright & Co.

Needham

Truist Securities

길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)의 주식은 수요일 7% 이상 상승 마감했다. 이는 화요일 회사가 2024년 4분기 조정 EPS가 1.90달러로, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">컨센서스 1.70달러를 초과</a>했다고 보고한 이후의 일이다.
매출은 작년 대비 6% 증가한 75.7억 달러로, 컨센서스인 71.4억 달러를 초과했다. 이는 주로 HIV 부문, 종양학 및 간질환 부문의 매출 증가로 인한 것이며, 베클루리(Veklury) (렘데시비르) 매출 감소로 일부 상쇄되었다.
HIV 매출은 16% 증가하여 54.5억 달러에 달했으며, <a href="https://s29.q4cdn.com/585078350/files/doc_financials/2024/q4/GILD-Q424-Summary-of-Prepared-Remarks-11-February-2025.pdf" target="_blank" rel="noreferrer noopener">수요 증가, 더 높은 실현 가격 및 재고 동향의 긍정적 영향</a>이 주요 원인이었다.
빅타비(Biktarvy)의 분기 매출은 31.2억 달러에서 38억 달러로 증가했다.
간질환 매출은 7.19억 달러로 4% 증가했으며, 이는 리브델지(Livdelzi)의 강력한 출시와 HBV/HDV 수요 증가에 기인한 것이지만, 환자 시작 감소로 인한 HCV 매출 감소가 일부 상쇄되었다.
배당금: 길리어드 사이언스는 분기 현금 배당금을 2.6% 인상하여 <a href="https://www.benzinga.com/pressreleases/25/02/b43640030/gilead-sciences-announces-2-6-percent-increase-in-first-quarter-2025-dividend" target="_blank" rel="noreferrer noopener">0.79달러로</a> 발표했다.
또한 읽어보기: <a href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" target="_blank" rel="noreferrer noopener">길리어드, 덜 빈번한 예방 접종 희망을 제공하는 새로운 연간 HIV 주사제 발표</a>
가이던스: 길리어드은 2025년 조정 EPS를 7.70달러-8.10달러로 예상하며, 컨센서스는 7.58달러이다. 매출은 28.2억 달러-28.6억 달러로 예상하며, 이는 컨센서스 28.42억 달러를 상회한다.
&#8220;상업적 강점을 바탕으로, 우리는 2025년 여름에 HIV PrEP용 레나카파비르(lenacapavir)의 잠재적 출시를 계획하고 있다. 이는 HIV 예방 범위를 확장할 수 있는 독특한 기회를 제공한다&#8221; 고 길리어드의 회장 겸 CEO인 다니엘 오데이(Daniel O&#8217;Day)가 말했다.
파이퍼 샌들러는 길리어드의 목표 주가를 105달러에서 110달러로 상향 조정했으며, <a href="https://www.benzinga.com/quote/GILD/analyst-ratings" target="_blank" rel="noreferrer noopener">비중 확대 등급은 변동 없음</a>을 유지했다. 분석가들은 올해 말 PrEP에서 레나카파비르의 상업적 출시와 몇 가지 중요한 후기 단계 결과 발표를 인용했다.
길리어드은 작년에 레나카파비르의 PrEP에 대한 규제 승인 신청서를 제출한 후, 여전히 2025년 상업적 출시 가능성을 기대하고 있다. 이는 회사가 PrEP 시장에서의 입지를 확보하고 환자 순응도를 개선하는 데 도움이 될 수 있다. 또한 2030년대 후반까지 HIV 리더십을 강화할 것이다.
골드만삭스는 길리어드이 레나카파비르 출시를 잘 준비하고 있다고 언급했다.
HIV 사업에 대해 골드만삭스의 애널리스트인 살빈 리히터(Salveen Richter)는 코멘트가 최근 투자자 행사와 대체로 일치했다고 전했다.
분석가는 카이트(Kite)와 트로델비(Trodelvy)에 영향을 미치는 경쟁으로 인해 종양학에서 어려움이 있다고 보지만, 아셀엑스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>)의 파트너십 치료제인 아니토셀(anito-cel)에 대한 긍정적인 전망을 유지하고, 트로델비의 확장을 주목하고 있다.
니덤의 애널리스트인 조셉 스트링거(Joseph Stringer)는 2025년에 가치를 주도할 두 가지 주요 이벤트가 있다고 보고한다: HIV 예방을 위한 레나카파비르의 출시 예상과 1차 전이성 삼중음성 유방암에 대한 트로델비의 3상 시험 업데이트이다.
애널리스트는 현재 수준에서 균형 잡힌 위험/보상으로 인해 길리어드에 대한 보유 등급을 유지하지만, 길리어드의 HIV 사업의 강력한 성과, 개선된 이익률, 레나카파비르의 매출 증가 잠재력에 대해 점점 더 낙관적으로 보고 있다.
가격 동향: 길리어드 사이언스의 주식은 수요일 7.46% 상승한 103.31달러에 마감되었다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43665455/te-connectivity-snaps-up-richards-manufacturing-for-2-3-billion-details" target="_blank" rel="noreferrer noopener">TE 커넥티비티, 리차드 제조사를 23억 달러에 인수</a></li>
</ul>
이미지 출처: Gilead Sciences
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Arcellx

뉴스

에 대한 최신 뉴스 Arcellx (NASDAQ:ACLX) 주식

수요일, 2월 12, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌